Acquisition by Chung In Chul of 20000 shares of Bellevue Life at 11.5 subject to Rule 16b-3

BLACDelisted Stock   3.01  0.88  22.62%   
About 59% of Bellevue Life's investor base is looking to short. The current sentiment regarding investing in Bellevue Life Sciences stock implies that many traders are alarmed. The current market sentiment, together with Bellevue Life's historical and current headlines, can help investors time the market. In addition, many technical investors use Bellevue Life Sciences stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Bellevue Life Sciences Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 20000 warrant for common stock at 11.5 of Bellevue Life by Chung In Chul on 15th of March 2024. This event was filed by Bellevue Life Sciences with SEC on 2023-02-14. Statement of changes in beneficial ownership - SEC Form 4

Bellevue Life Fundamental Analysis

We analyze Bellevue Life's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bellevue Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bellevue Life based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Employees

Number Of Employees Comparative Analysis

Bellevue Life is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.

Bellevue Life Sciences Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bellevue Life stock to make a market-neutral strategy. Peer analysis of Bellevue Life could also be used in its relative valuation, which is a method of valuing Bellevue Life by comparing valuation metrics with similar companies.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Consideration for investing in Bellevue Stock

If you are still planning to invest in Bellevue Life Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellevue Life's history and understand the potential risks before investing.
Global Correlations
Find global opportunities by holding instruments from different markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device